Lumbar interbody fusion with porous biphasic calcium phosphate enhanced by recombinant human bone morphogenetic protein-2/silk fibroin sustained-release microsphere in a sheep model

doi:10.3969/j.issn.2095-4344.2017.26.014

Abstract

Abstract:

BACKGROUND: The authors have studied the porosity, pore size, mechanical strength, in vitro biological activity, ectopic osteogenic activity of porous biphasic calcium phosphate enhanced by recombinant bone morphogenetic protein-2/silk fibroin sustained-release microsphere (BCP/rBMP-2/SF). However, further investigation on the osteogenic ability of the composite bone graft material is warranted based on a reliable animal model, which will provide experimental data for the clinical application of the composite material in the spinal fusion.

OBJECTIVE: To investigate the osteogenic efficacy of BCP/rBMP-2/SF in a sheep lumbar interbody fusion model.

METHODS: Sixteen healthy adult sheep were divided into two groups randomly. All sheep were operated on the left extraperitoneal approach and intervertebral discs of L_1/2, L_3/4, and L_5/6 were exposed respectively. Three of the following four materials were randomly implanted into the L_1/2, L_3/4, and L_5/6 of each animal: autologous iliac, BCP/rhBMP-2/SF, BCP/rhBMP-2 or BCP/SF.

RESULTS AND CONCLUSION: The group of BCP/SF/rhBMP-2 achieved a similar fusion rate compared with the group of autologous iliac at 12 and 24 weeks after operation, and they were significantly better than the other two groups. These findings indicate that the novel new artificial bone, BCP/rhBMP-2/SF, can obtain similar lumbar fusion results compared with the autologous iliac. It is expected to be applied to clinical practice in the future by further improving its properties.

中国组织工程研究杂志出版内容重点：生物材料；骨生物材料; 口腔生物材料; 纳米材料; 缓释材料; 材料相容性；组织工程

Key words: Calcium Phosphates, Silk, Bone Morphogenetic Proteins

CLC Number:

R318

Liu Hai-long, Chen Liang, Gu Yong, Wang Chun-zeng, Liu Yue-hong.

Lumbar interbody fusion with porous biphasic calcium phosphate enhanced by recombinant human bone morphogenetic protein-2/silk fibroin sustained-release microsphere in a sheep model

[J]. Chinese Journal of Tissue Engineering Research, 2017, 21(26): 4178-4184.

Figures/Tables 7

References

[1]Gruskay JA, Webb ML, Grauer JN. Methods of evaluating lumbar and cervical fusion. Spine J. 2014;14(3):531-539.

[2]Malham GM, Parker RM, Ellis NJ, et al. Anterior lumbar interbody fusion using recombinant human bone morphogenetic protein-2: a prospective study of complications. J Neurosurg Spine. 2014;21(6):851-860.

[3]Liao JC, Chen WJ, Chen LH, et al. Surgical outcomes of degenerative spondylolisthesis with L5-S1 disc degeneration: comparison between lumbar floating fusion and lumbosacral fusion at a minimum 5-year follow-up. Spine (Phila Pa 1976). 2011;36(19):1600-1607.

[4]Rezwan K, Chen QZ, Blaker JJ, et al. Biodegradable and bioactive porous polymer/inorganic composite scaffolds for bone tissue engineering. Biomaterials. 2006;27(18): 3413-3431.

[5]Grauer JN, Beiner JM, Kwon B, et al. The evolution of allograft bone for spinal applications. Orthopedics. 2005; 28(6):573-577; quiz 578-579.

[6]Majid K, Tseng MD, Baker KC, et al. Biomimetic calcium phosphate coatings as bone morphogenetic protein delivery systems in spinal fusion. Spine J. 2011;11(6):560-567.

[7]Marie PJ, Debiais F, Haÿ E. Regulation of human cranial osteoblast phenotype by FGF-2, FGFR-2 and BMP-2 signaling. Histol Histopathol. 2002;17(3):877-885.

[8]Lad SP, Nathan JK, Boakye M. Trends in the use of bone morphogenetic protein as a substitute to autologous iliac crest bone grafting for spinal fusion procedures in the United States. Spine (Phila Pa 1976). 2011;36(4):E274-281.

[9]Boerckel JD, Kolambkar YM, Dupont KM, et al. Effects of protein dose and delivery system on BMP-mediated bone regeneration. Biomaterials. 2011;32(22):5241-5251.

[10]Autefage H, Briand-Mésange F, Cazalbou S, et al. Adsorption and release of BMP-2 on nanocrystalline apatite-coated and uncoated hydroxyapatite/beta-tricalcium phosphate porous ceramics. J Biomed Mater Res B Appl Biomater. 2009; 91(2): 706-715.

[11]Chen L, Gu Y, Feng Y, et al. Bioactivity of porous biphasic calcium phosphate enhanced by recombinant human bone morphogenetic protein 2/silk fibroin microsphere. J Mater Sci Mater Med. 2014;25(7):1709-1719.

[12]Gu Y, Chen L, Yang HL, et al. Evaluation of an injectable silk fibroin enhanced calcium phosphate cement loaded with human recombinant bone morphogenetic protein-2 in ovine lumbar interbody fusion. J Biomed Mater Res A. 2011;97(2): 177-185.

[13]Murugan R, Ramakrishna S. Bioresorbable composite bone paste using polysaccharide based nano hydroxyapatite. Biomaterials. 2004;25(17):3829-3835.

[14]Smucker JD, Bobst JA, Petersen EB, et al. B2A peptide on ceramic granules enhance posterolateral spinal fusion in rabbits compared with autograft. Spine (Phila Pa 1976). 2008;33(12):1324-1329.

[15]Blattert TR, Delling G, Dalal PS, et al. Successful transpedicular lumbar interbody fusion by means of a composite of osteogenic protein-1 (rhBMP-7) and hydroxyapatite carrier: a comparison with autograft and hydroxyapatite in the sheep spine. Spine (Phila Pa 1976). 2002;27(23):2697-2705.

[16]Lysack JT, Yen D, Dumas GA. In vitro flexibility of an experimental pedicle screw and plate instrumentation system on the porcine lumbar spine. Med Eng Phys. 2000;22(7): 461-468.

[17]Abbah SA, Lam CX, Ramruttun AK, et al. Fusion performance of low-dose recombinant human bone morphogenetic protein 2 and bone marrow-derived multipotent stromal cells in biodegradable scaffolds: a comparative study in a large animal model of anterior lumbar interbody fusion. Spine (Phila Pa 1976). 2011;36(21):1752-1759.

[18]Smucker JD, Bobst JA, Petersen EB, et al. B2A peptide on ceramic granules enhance posterolateral spinal fusion in rabbits compared with autograft. Spine (Phila Pa 1976). 2008; 33(12):1324-1329.

[19]Akita S, Fukui M, Nakagawa H, et al. Cranial bone defect healing is accelerated by mesenchymal stem cells induced by coadministration of bone morphogenetic protein-2 and basic fibroblast growth factor. Wound Repair Regen. 2004;12(2): 252-259.

[20]Liu X, Ma PX. The nanofibrous architecture of poly(L-lactic acid)-based functional copolymers. Biomaterials. 2010; 31(2):259-269.

[21]Lou T, Wang X, Song G. Fabrication of nano-fibrous poly(L-lactic acid) scaffold reinforced by surface modified chitosan micro-fiber. Int J Biol Macromol. 2013;61:353-358.

[22]Chen VJ, Ma PX. Nano-fibrous poly(L-lactic acid) scaffolds with interconnected spherical macropores. Biomaterials. 2004;25(11):2065-2073.

[23]Liu X, Won Y, Ma PX. Porogen-induced surface modification of nano-fibrous poly(L-lactic acid) scaffolds for tissue engineering. Biomaterials. 2006;27(21):3980-3987.

[24]Qiao C, Zhang K, Jin H, et al. Using poly(lactic-co-glycolic acid) microspheres to encapsulate plasmid of bone morphogenetic protein 2/polyethylenimine nanoparticles to promote bone formation in vitro and in vivo. Int J Nanomedicine. 2013;8:2985-2995.

[25]Qiao C, Zhang K, Sun B, et al. Sustained release poly (lactic-co-glycolic acid) microspheres of bone morphogenetic protein 2 plasmid/calcium phosphate to promote in vitro bone formation and in vivo ectopic osteogenesis. Am J Transl Res. 2015;7(12):2561-2572.

[26]Atluri K, Seabold D, Hong L, et al. Nanoplex-Mediated Codelivery of Fibroblast Growth Factor and Bone Morphogenetic Protein Genes Promotes Osteogenesis in Human Adipocyte-Derived Mesenchymal Stem Cells. Mol Pharm. 2015;12(8):3032-3042.

[27]Jin H, Zhang K, Qiao C, et al. Efficiently engineered cell sheet using a complex of polyethylenimine-alginate nanocomposites plus bone morphogenetic protein 2 gene to promote new bone formation. Int J Nanomedicine. 2014;9: 2179-2190.

[28]Xu X, Qiu S, Zhang Y, et al. PELA microspheres with encapsulated arginine-chitosan/pBMP-2 nanoparticles induce pBMP-2 controlled-release, transfected osteoblastic progenitor cells, and promoted osteogenic differentiation. Artif Cells Nanomed Biotechnol. 2017;45(2):330-339.

[29]陈亮,顾勇,陈晓庆,等.丝素蛋白增强型磷酸钙复合rhBMP-2用于绵羊腰椎椎体间融合的实验研究[J].中华骨科杂志,2010, 30(7): 677-683.

[30]Bessa PC, Casal M, Reis RL. Bone morphogenetic proteins in tissue engineering: the road from laboratory to clinic, part II (BMP delivery). J Tissue Eng Regen Med. 2008;2(2-3):81-96.